Singapore, Jan. 12 -- China-based MediLink Therapeutics has entered into a new collaboration and exclusive licensing agreement with Roche for the development and commercialisation of YL201, an investigational novel antibody-drug conjugate (ADC) asset targeting B7H3 across numerous solid tumour types.

Under the terms of the agreement, MediLink will grant Roche an exclusive license to develop, manufacture, and commercialise YL201 worldwide, excluding the mainland of China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region.

MediLink will receive upfront and near-term milestone payments of $570 million, together with additional development, regulatory, and commercial milestone payments, as well as tier...